I
Istari Oncology
Istari Oncology, Inc. is a clinical-stage biotechnology company dedicated to developing innovative immuno-oncology and immunotherapy platforms aimed at treating glioblastoma and a broad range of…
About Istari Oncology
iStar Oncology is a biotech startup that operates in the field of cancer therapy. The company's primary product is lerapolturev, a treatment based on the live attenuated Sabin type 1 oral polio vaccine. This treatment leverages the immune system's memory response to polio to amplify the anticancer immune response. The company's approach is designed to overcome the challenges faced by immune checkpoint inhibitors, which have revolutionized cancer therapy but are limited by a lack of preexisting anticancer T cells or the inability of these cells to overcome the immunosuppressive tumor environment.
The company's business model revolves around the development and clinical testing of lerapolturev. The drug has been administered to over 200 patients and is currently the subject of multiple ongoing phase 2 trials across various solid tumors. The company's target market includes patients with various types of solid tumors, as the poliovirus receptor, which lerapolturev targets, is present on virtually all solid tumor types.
iStar Oncology generates revenue through the development, testing, and potential future sales of its cancer therapy. The company has received Orphan Drug Designation and Breakthrough Therapy Designation for recurrent glioblastoma (rGBM) from the FDA. It has also been granted Fast Track status for patients with advanced melanoma who have disease progression after anti–PD-1/L1 therapy.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Apr 2021 | $43M | $174M | Undisclosed | — |
| EARLY VC✓Equity / VC | May 2017 | $1.1M | $4.4M | Undisclosed | — |
Growth signals
Latest recorded traffic for Istari Oncology is 190 monthly website visits, down 90% over the last three months. Istari Oncology's team declined 50% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Istari Oncology in the Durham ecosystem
The Istari Oncology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Other known investors2 additional known investors
Duke University
Pappas Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Istari Oncology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Istari Oncology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









